Regulation of QT indices mediated by autonomic nervous function in patients with type 2 diabetes.
Both the QT interval and QT dispersion in diabetic patients have been reported to increase with the progression of cardiac autonomic neuropathy and to have a prognostic value. We assessed the cardiac autonomic influences on QT indices using the measurements of baroreflex sensitivity, heart rate variability, and cardiac (123)I-metaiodobenzylguanidine scintigraphic findings in patients with type 2 diabetes mellitus. Forty-two consecutive patients with type 2 diabetes (mean+/-SD: 54+/-10 years, 22 women and 20 men) were studied. Baroreflex sensitivity negatively correlated with the maximum and minimum QTc intervals as well as QT/QTc dispersion. However, the high-frequency power and the ratio of low-frequency power to high-frequency power of heart rate variability did not correlate with any QT indices. The percent washout rate of (123)I-metaiodobenzylguanidine positively correlated with QT/QTc dispersion, but not with maximum and minimum QTc intervals. Our findings suggest that cardiac vagal dysfunction is related to QT interval prolongation while both sympathetic and vagal dysfunctions are related to increased QT dispersion in type 2 diabetic patients. Baroreflex sensitivity and percent washout rate of (123)I-metaiodobenzylguanidine may be useful parameters indicating the abnormalities of the cardiac ventricular repolarization in this population.
Takahashi
Naohiko
N
Department of Internal Medicine I, School of Medicine, Oita Medical University, 1-1 Idaigaoka, Hasama, Oita 879-5593, Japan. takanao@oita-med.ac.jp
Nakagawa
Mikiko
M
Saikawa
Tetsunori
T
Watanabe
Maki
M
Ooie
Tatsuhiko
T
Yufu
Kunio
K
Shigematsu
Sakuji
S
Hara
Masahide
M
Sakino
Hiroshi
H
Katsuragi
Isao
I
Tanaka
Katsuhiro
K
Yoshimatsu
Hironobu
H
D019797:3-Iodobenzylguanidine / Q000493:pharmacokinetics; D000328:Adult; D000368:Aged; D001341:Autonomic Nervous System / Q000000981:diagnostic imaging / Q000503:physiopathology*; D017704:Baroreflex / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000000981:diagnostic imaging / Q000503:physiopathology*; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging / Q000503:physiopathology*; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine